Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Taiwan
Management Report
Published: January 2010
Pages: 42
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Taiwan is one of the richest countries in the Asia Pacific region. It has a strong healthcare system and the universal health insurance ensures that all citizens have grown to expect a high level of care. That said, like a lot of public welfare systems, the healthcare system is being constrained by rising costs, and a rapidly growing elderly population is adding to this.
In January 2009, the USTR removed Taiwan from its Special 301 Watch List of countries, attributing the move to the country’s progress on protection and enforcement of intellectual property rights. It is a marked difference compared to when the USTR described the country as a “haven for pirates” in 2001, the year it was first placed on the list.
From 1st January 2010, ultimate responsibility for pharmaceutical regulation rests with the newly-created Food and Drug Administration (FDA). This newly-created agency streamlines four cabinet bureaus formerly under the control of the Department of Health (DOH). The FDA integrates the functions of the Bureau of Food Sanitation, the Bureau of Pharmaceutical Affairs, the National Laboratories of Foods and Drugs, and the National Bureau of Controlled Drugs and will have a staff of 505 people. The creation of this agency was accelerated following the importation of melamine-tainted dairy products from China in 2008.
Taiwan’s growing export-oriented API producers are focusing on more “high-end” products with higher profit margins in order to differentiate themselves from API producers in India and China. Compared to pharmaceutical products and Chinese herbal medicines, both categories which have seen production output decline, API production output has bucked the trend, mainly due to rising international orders.
In March 2009, it was announced that the Science and Technology Advisory Group (STAG) of the Executive Yuan (Taiwan’s cabinet) is to unveil a NT$60 billion (US$1.8 billion) biotech venture capital fund, with the aim of doubling the annual output of the country’s biotech industry to NT$300 billion (US$8.8 billion) in four years.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
In January 2009, the USTR removed Taiwan from its Special 301 Watch List of countries, attributing the move to the country’s progress on protection and enforcement of intellectual property rights. It is a marked difference compared to when the USTR described the country as a “haven for pirates” in 2001, the year it was first placed on the list.
From 1st January 2010, ultimate responsibility for pharmaceutical regulation rests with the newly-created Food and Drug Administration (FDA). This newly-created agency streamlines four cabinet bureaus formerly under the control of the Department of Health (DOH). The FDA integrates the functions of the Bureau of Food Sanitation, the Bureau of Pharmaceutical Affairs, the National Laboratories of Foods and Drugs, and the National Bureau of Controlled Drugs and will have a staff of 505 people. The creation of this agency was accelerated following the importation of melamine-tainted dairy products from China in 2008.
Taiwan’s growing export-oriented API producers are focusing on more “high-end” products with higher profit margins in order to differentiate themselves from API producers in India and China. Compared to pharmaceutical products and Chinese herbal medicines, both categories which have seen production output decline, API production output has bucked the trend, mainly due to rising international orders.
In March 2009, it was announced that the Science and Technology Advisory Group (STAG) of the Executive Yuan (Taiwan’s cabinet) is to unveil a NT$60 billion (US$1.8 billion) biotech venture capital fund, with the aim of doubling the annual output of the country’s biotech industry to NT$300 billion (US$8.8 billion) in four years.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.